Bright light therapy in people with a moderate to severe dementia and a depressive disorder

Completed

• Conditions: depressive disorder; 10027946

• Registration Number: NL-OMON41993
• Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 80

Inclusion Criteria

* Age: 65 years and older
* Diagnosis of dementia. The patient must be diagnosed by a doctor (general practitioner, geriatrician, neurologist, geriatric specialist).
* Diagnosis of depression: either major depressive disorder, or limited depression. This diagnosis is made by the (GZ-) psychologist of the nursing home department, according to the Multidisciplinaire Richtlijn Depressie, addendum Ouderen, of Trimbos Instituut, from which the ' Provisional Diagnostic Criteria for Depression in Alzheimer's Disease ' (Olin et al., 2002) are used. The Cornell Scale for Depression in Dementia (CSDD) is used as a screening instrument.

Exclusion Criteria

* Other neurological disorders (such as non-congenital brain damage or Korsakov's syndrome, Parkinson and Huntington), except for CVA belonging to vascular dementia.
* Other psychiatric disorders (such as bipolar disorder, anxiety disorder or psychosis)
* Serious eye conditions (for example, macular degeneration or eye conditions as a result of diabetes), where there is a contraindication to BLT
* Sensitivity to light (e.g. as a result of epilepsy)
* Highly elevated blood pressure syst > 200
For each participant the doctor of the nursing home department will determine whether BLT is medically justified.

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>-Number of clients that fully completed the BLT treatment protocol<br /><br>-Description of the way the protocol is executed<br /><br>-Frequency and nature of the required adjustments to the protocol<br /><br>-Frequency and nature of side effects</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Change in level of depressive symptoms.</p><br>